Method for treating the cases of herpetic otoinfection

FIELD: medicine.

SUBSTANCE: method involves applying antiherpetic therapy using Phamcyclovir. Then, Trental is sequentially introduced during 5 days with 2-5 ml of cerebrolysin being concurrently intratissularly introduced behind mastoid process tip. Mexidol is administered for 10 days. The treatment is finished by introducing Polyoxydonium.

EFFECT: combined microcirculation improvement; high neurotrophic and antioxidant activity; secondary immune deficiency adjustment; eliminated labyrinth hydrops.

 

The invention relates to medicine, namely to the treatment of vestibular and auditory abnormalities in herpes autoinfection.

Currently, worldwide there is a steady growth in the number of cases of recurrent herpes infection [1]. The diversity of clinical manifestations of persistent herpes infection, recurrent nature of the flow, the possibility of its spread almost all known transmission routes has allowed to carry herpes infection in a group of diseases that determine the future of all infectious diseases [2]. Illnesses caused by herpes simplex virus, have high neurotransmi, including receptor formations of the inner ear [3]. Latent current herpes infection underlies chronic kohleovestibulyarnye dysfunction [4].

There is a method of treating herpes autoinfection [5], which consists in prescribing antiviral drugs, such as famciclovir, acyclovir. The disadvantage of this treatment is the lack of correction of immune status.

The closest way to treat herpes autoinfection [6] is a method, including the appointment of Antiherpes virus effect means, for example, famciclovir, and holding immunomodulatory therapy with polyoxidonium, cycloferon, Viferon. This method is ecene allows to reduce terms of recurrence and extend miracidium period. The disadvantage of this method is that there is no correction of the secondary vascular disorders.

The aim of the invention is to increase the efficiency of treatment by reducing the number of relapses, halting the spread of HSV, correction of microcirculatory changes in the system of the inner ear.

This objective is achieved in that in the method of treating herpes autoinfective, including the appointment of Antiherpes virus effect means, for example, famciclovir, and holding immunomodulatory therapy with polyoxidonium, according to the invention after the course Antiherpes virus effect of therapy prescribed drugs with complex metabolic and vasoactive effect and Cerebrolysin, influencing processes of plasticity with a multimodal effect on the metabolism of the brain, with the introduction of Cerebrolysin spend interstitial behind the top of the mastoid process.

As a drug with complex metabolic and vasoactive action prescribed trental or months.

A feature of the invention lies in the fact that the appointment of agents with complex metabolic and vasoactive action after the course Antiherpes virus effect of therapies aimed at the inclusion of compensatory mechanisms, the normalization of vascular tone, improve blood circulation balance is about and auditory analyzer, correction of metabolic abnormalities and subsequent interstitial introduction of Cerebrolysin behind the top of the mastoid process provides neurotrophic, anti-oxidant and improves microcirculation in the area of introduction. At the final stage of treatment is correction of secondary immunodeficiency States.

The method is as follows.

In the diagnosis of peripheral kohleovestibulyarnye syndrome appoint: taking famciclovir 0.25 g and 0.5 g 3 times a day or 0.75 1 g once a day for 7 to 10 days. 8-11 day begin infusion trental 0.1 g 2% (5 ml) in 200 ml of 0.9% isotonic sodium chloride solution, 5 days; at the same time is the introduction of Cerebrolysin in 2-5 ml of interstitial behind the top mastoid No. 10. 13-16 per day is the infusion of Mexidol 2-4 ml of 5% solution in 200 ml of 0.9% isotonic sodium chloride solution for 10 days. 22-25 day appointed polyoxidonium 6 mg intramuscularly every other day No. 5, further 2 times a week (course of 10 injections).

Examples of specific implementation of the proposed method of treatment.

Patient I., 41. The diagnosis of Meniere's Disease herpetic etiology (peripheral kohleovestibulyarnye syndrome).

Held: Famciclovir 0.25 g 3 times a day for 7 days, then on the 8th day right infusion trental 5 ml in 200 ml of 0.9% isotonic solution netrecord, 5 days; simultaneously interstitial introduction of Cerebrolysin 2 ml behind the top mastoid No. 10. On the 13 day was conducted infusion of Mexidol 2 ml of 5% solution in 200 ml of 0.9% isotonic sodium chloride solution for 10 days. On the 22nd day appointed polyoxidonium 6 mg intramuscularly every other day No. 5, further 2 times a week (course of 10 injections).

After treatment of seizures dizziness system with marked autonomic reaction was not observed during the year, improved hearing according to the loss of 15 dB at 3 frequencies, cleared hydrops of the maze (PDI=1,2), there is no noise in the ears.

Patient, 30 years. The diagnosis of Relapsing herpetic labyrinthitis (peripheral kohleovestibulyarnye syndrome).

Held: Famciclovir 0.25 g 3 times a day for 7 days, then on the 8th day right infusion trental 5 ml in 200 ml of 0.9% isotonic sodium chloride solution, 5 days; simultaneously interstitial introduction of Cerebrolysin 2 ml behind the top mastoid No. 10. On the 13 day was conducted infusion of Mexidol 2 ml of 5% solution in 200 ml of 0.9% isotonic sodium chloride solution for 10 days. On the 22nd day appointed polyoxidonium 6 mg intramuscularly every other day No. 5, further 2 times a week (course of 10 injections).

After treatment vertigo, ataxia and autonomic manifestations were absent. The hearing according to the audiometry - improving the bone conduction thresholds by 10 dB. There is no noise in the ears. At follow-up within 1 year of such violation was not observed, the hearing without the negative dynamics.

Patient I., 52 years old. The diagnosis of Meniere's Disease herpetic etiology (peripheral kohleovestibulyarnye syndrome).

Held: Famciclovir 0.25 g 3 times a day for 7 days, then on the 8th day right infusion trental 5 ml in 200 ml of 0.9% isotonic sodium chloride solution, 5 days; simultaneously interstitial introduction of Cerebrolysin 2 ml behind the top mastoid No. 10. On the 13 day was conducted infusion of Mexidol 2 ml of 5% solution in 200 ml of 0.9% isotonic sodium chloride solution for 10 days. On the 22nd day appointed polyoxidonium 6 mg intramuscularly every other day No. 5, further 2 times a week (course of 10 injections). After treatment system attacks of vertigo with severe autonomic reaction was not observed within two years, improved hearing according to the loss of 10 dB at 3 frequencies, cleared hydrops of the maze (PDI=1,5), significantly decreased the intensity of noise in the ears.

Thus, the proposed method allows to stop the spread of herpes simplex virus, to reduce the number of relapses and increase miracidium period of chronic recurrent herpetic infection, relieve hydrops of the maze and stop the dizziness and improve auditory function

A new method for the treatment of herpes autoinfection can be applied in outpatient and inpatient treatment of patients with chronic peripheral kohleovestibulyarnye dysfunction herpetic etiology.

Sources of information

1. Deconinck H.E. herpes Virus and damage to the nervous system / Appearance // Russian medical journal. - 2002. No. 4. - P.46-49.

2. Granite V.M. Herpes virus infection / Vmenu. - N. Novgorod: Publishing house of the Nizhniy Novgorod state medical Academy, 2001. - 88 C.

3. Nalimov T.A. Viral infection in ENT practice / Casaliva, Yegorova // Proceedings of the V scientific-practical conference "Modern technologies in medicine". - Nyagan, 2003. - P.35-36.

4. Babiak VI Neuropathology: a Guide for physicians / Viebig, Vurgaftman, Ahankara.- SPb.: Hippocrates, 2002. - 728 S.

5. Federal guidance on the use of drugs (formulary system). - M.: ECHO, 2004. Edition V. - 944 S.

6. Samghin M.A. herpes simplex (Dermatological aspects) / Massagen, Havn. - M: MED presentors, 2002. - 160 S.

A method of treating herpes autoinfective, including Antiherpes virus effect of therapy famciclovir, as well as the conduct of immunomodulatory therapy with polyoxidonium, characterized in that after the course Antiherpes virus effect of therapy consistently give trental is for 5 days with simultaneous interstitial introduction 2-5 ml Cerebrolysin behind the top of the mastoid process, then Mexidol for 10 days and complete the treatment with the introduction of polyoxidonium.



 

Same patents:

FIELD: veterinary science.

SUBSTANCE: method involves using the preparation "Furatsiklin M" in the dose 0.5 g/kg of living mass with additional using the preparation "Immunobak" as 3 doses per a head. Preparations are administrated in chickens of age 120, 140 and 300 days by oral route, 2 times per 24 h, for 5 days by three courses. Method promotes to effective neutralization of the disease pathogen, enhanced resistance of chicken body and recoveries biocenosis after termination of treatment. Invention can be used in treatment of mycoplasmosis in chickens.

EFFECT: improved and enhanced effectiveness of treatment.

12 tbl, 2 ex

FIELD: veterinary science.

SUBSTANCE: invention involves the combined use of antibacterial preparations and immunomodulator. Method involves complex of single and double RNA sodium salts from killer yeast Saccharomyces cerevisiae as an immunomodulator and synthetic polymer-carrier taken in the dose 0.3-0.4 mg/kg. Immunomodulator is administrated in animals in a single dose before onset of critical period, i. e. in 15-20 days of piglets growing. Method provides stimulation of factors of cellular and humoral immunity of animals without adverse reactions and complication due to selection of optimal dose of immunomodulator and its prolonged effect.

EFFECT: improved method for treatment and prophylaxis.

3 cl, 4 tbl, 3 ex

FIELD: medicine, pediatrics, pulmonology, allergology.

SUBSTANCE: method involves administration of viferon by rectal way. Viferon-1 is dosed to children of age 3-6 years (150000 IU in one suppository), and viferon-2 is dosed to children of age 7-14 years (500000 IU in one suppository) every day, twice per a day, for 10 days and then for 4 weeks in every other day. Proposed invention promotes to decrease numbers of bronchial asthma exacerbation, diminishing degree of bronchial asthma severe attack, decreasing frequency of bronchial asthma, increasing period of bronchial asthma remission due to activation of the interferon system. Invention can be used in treatment of bronchial asthma in children suffering from ARVI often and/or for a long time.

EFFECT: enhanced effectiveness of treatment.

6 tbl, 3 ex

FIELD: pharmaceutical industry, in particular immunomodulating agents and production of pharmaceutical compositions containing the same.

SUBSTANCE: claimed immunomodulating agent represents complex of monosulfated cucumariosides with sterol in molar ratio cucumariosides/sterol of 1:2. Said complex is obtained by addition of sterol solution to extract from Cucumaria japonica, or extract of wastewater from Cucumaria japonica processing, or cucumarioside solution. As sterol solution cholesterol or sitosterol. Pharmaceutical composition having immunomodulating activity contains abovementioned agent and filler in specific component ratio.

EFFECT: non-toxic pharmaceutical composition useful as tumor inhibitory agent.

4 cl, 11 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: one should carry out antibacterial and infusion therapy. Moreover, additionally, after compensating the volume of circulating blood during infusion therapy one should intravenously inject 30 thousand IU antigangrenous polyvalent equine serum by drops per 200 ml isotonic NaCl solution: the first 1 ml solution should be injected for 5 min, the rest volume - for 1-1.5 h. The innovation suggested enables to optimize immunocorrecting therapy without sensitizing patient's body.

EFFECT: higher efficiency of therapy.

3 ex, 1 tbl

FIELD: pharmaceutical industry, in particular drug containing human recombinant alpha-2 interferon.

SUBSTANCE: claimed prolonged solution contains human recombinant alpha-2 interferon, citric acid, boric acid, sodium tetraborate, unithiol, human serum albumin, sodium chloride, sodium carboxymethylcellulose and purified water. Preparation of present invention has wide spectrum of therapeutic application.

EFFECT: drug of high specific antiviral and antimicrobial activity without side effects.

1 tbl, 3 ex

FIELD: medicine, pediatrics.

SUBSTANCE: in small children at syndrome of increased thymus gland degree 1-3 one should prescribe prednisolone and eubiotics simultaneously, and at degree 2-3 it is necessary to prescribe immunomodulating agents, additionally. The innovation provides increased anti-infectious immunity and inspecific body resistance due to efficient correction of hormonal state in this group of children.

EFFECT: higher efficiency of prophylaxis.

2 cl, 1 ex

FIELD: veterinary obstetrics.

SUBSTANCE: the method deals with subcutaneous injection of bioglobin (placenta denaturated suspended - PDS) at the quantity of 20 mg/animal/d not earlier that 10 d before calving. The innovation enables to increase quality in preventing the onset of functional dyspepsia in newborn calves and level of total body resistance.

EFFECT: higher efficiency.

20 dwg, 1 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vestibular and auditory disorders, trigeminal nerve's neuralgia and peripheral paresis of facial nerve of herpetic etiology. The method deals with introduction of an antiherpetic preparation followed by immunomodelling therapy with the use of polyoxidonium. Moreover, after treating with antiherpetic preparation before introducing polyoxidonium it is necessary to conduct additional successive therapy: with preparations of trophic action as milgamma or neuromultivit at simultaneous introduction of antioxidant, then comes intratissue injection of cerebrolysine being behind the top of mastoid process.

EFFECT: the innovation enables to decrease the quantity of relapses due to stopping the development of herpes simplex virus, restore conductivity along nervous fiber and improve endoneural circulation.

3 cl, 3 ex

Medicinal agent // 2268037

FIELD: medicine, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to using 4-chloro-2-methylphenoxyacetic acid of the formula (I)

and its pharmacologically acceptable sodium, potassium and lithium salts (mixture of these salts, or mixture of salts and 4-chloro-2-methylphenoxyacetic acid) as a medicinal agent possessing immunomodulating, anti-inflammatory and antitumor properties, and antiviral activity also. 4-Chloro-2-methylphenoxyacetic acid and its mixtures with pharmacologically acceptable alkaline metal salts possess high effectiveness and enhanced bioavailability.

EFFECT: valuable medicinal properties of medicinal agent.

9 cl, 13 ex

FIELD: immunology, biotechnology.

SUBSTANCE: invention describes antibody and its fragments neutralizing rabies virus and a method for treatment of patient subjected for effect of rabies virus by using indicated antibody and its fragment. Invention discloses variants of isolated nucleic acids encoding polypeptides carrying light and heavy chain of antibody, respectively. Also, invention describes expressing vector carrying at least one of indicated nucleic acids. Using this invention enhances span-life of patients after effect with rabies virus on them and can be used in corresponding prophylactic therapy of such patients.

EFFECT: valuable medicinal properties of antibody and nucleic acid.

14 cl, 1 dwg, 1 tbl, 2 ex

FIELD: medicine, organic chemistry, pharmacy.

SUBSTANCE: invention relates to an antibacterial preparation based on α-aminosulfonic acid amide, i. e. N'-methyl-1-phenyl-1-N,N-diethylaminomethanesulfonamide that can be used in veterinary science. Invention relates to expanding assortment of agents used against pathogenic pathogen with a preparation relating to class of α-aminosulfonic acid amides eliciting antibacterial activity being without cumulative properties and pathological changes in animal organs and tissues.

EFFECT: valuable veterinary properties of preparation.

1 tbl, 1 ex

FIELD: medicine, immunology.

SUBSTANCE: vaccine Rudivax is administered to group of girls not younger than 13 years old leaving Thule regions not later than 55 days before departure. Similarly group of homing girls not younger than 13 years old are vaccinated not early than 90 days after coming in Thule regions from other climatic regions.

EFFECT: presence of protective titers of anti-rubella antibodies in vaccinated girls for 1 year after vaccination.

6 ex

FIELD: veterinary virology and biotechnology.

SUBSTANCE: claimed vaccine contains antigen material from infective cattle rinotracheitis virus strain, reproduced in specific passage cell cultures having biological activity of at least 6.0 lg TCD50/cm3 and inactivated with aminoethyl ethyleneimine, and oily adjuvant in mass ratio of 30.0:70.0, respectively. Aforementioned virus strain is reproduced in specific passage cell cultures and has cytopathic action and during incubation for 48-96 h in accumulated in titer of 6.5-8.0 lg TCD50/cm3. Aminoethyl ethyleneimine is used in concentration of 0.1-0.2 % followed by neutralization thereof with sodium thiosulfate.

EFFECT: vaccine with high antigenic and immunogenic activity and safety; enhanced assortment of specific agents for infective cattle rinotracheitis prophylaxis.

15 cl, 6 tbl, 7 ex

FIELD: medicine, polymers, virology, pharmacy.

SUBSTANCE: invention relates to new derivative of gossypol representing gossypol and carboxymethylcellulose copolymer sodium salt. Gossypol and carboxymethylcellolose copolymer sodium salt represents compound of the formula (I):

wherein a : b : c = 1:(3-6):(5-7), respectively, with molecular mass 120000-130000 Da and the replacing degree 0.35-0.80. Pharmaceutical preparation possessing with antiviral activity comprises gossypol and carboxymethylcellulose copolymer sodium salt of abovementioned formula and pharmaceutically acceptable carrier or excipient. Method for treatment of herpes infection involves administration the effective dose of abovementioned pharmaceutical preparation in the patient. Invention provides preparing compound possessing the enhanced solubility and diminished toxicity.

EFFECT: improved method for prophylaxis and treatment, valuable medicinal properties of copolymer.

5 cl, 3 tbl, 16 ex

FIELD: pharmaceutical industry, in particular drug containing human recombinant alpha-2 interferon.

SUBSTANCE: claimed prolonged solution contains human recombinant alpha-2 interferon, citric acid, boric acid, sodium tetraborate, unithiol, human serum albumin, sodium chloride, sodium carboxymethylcellulose and purified water. Preparation of present invention has wide spectrum of therapeutic application.

EFFECT: drug of high specific antiviral and antimicrobial activity without side effects.

1 tbl, 3 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a medicinal preparation used in treatment of viral diseases and prophylaxis of infectious epizootic processes. The preparation comprises an active substance prepared on the base of antimony and represents a finely crystalline sorbent consisting of structural links of the formula:

and having particles size (1 x 10-5)-(9 x 10-5)μm and used in the dose 100-120 mg/kg. The preparation represents suspension for intramuscular or intravenous administration or it can be included into capsules for oral intake. The prepared preparation possesses higher antiviral activity and broader spectrum of antiviral effect.

EFFECT: improved and valuable medicinal properties of preparation.

3 cl, 8 tbl, 5 ex

FIELD: medicine, pediatrics.

SUBSTANCE: children who are not 6 yr old since April to July should be revaccinated with alive parotitis vaccine next year only, during the same period - since April to July. The innovation provides development of tense immunity in 6-yr-old children.

EFFECT: higher efficiency of revaccination.

12 ex

FIELD: medicine, infectious diseases, psychotherapy.

SUBSTANCE: method involves antiviral therapy, immune correction with thymus hormones and interferon inductors. Since the first day the relapse symptom method involves prescription of antiox+ (1 capsule per a day) and detox+ (1 capsule, 2 times per a day) for 30 days, profluzak (20 mg, 3 times per a day for 5 days) and then in the dose 20 mg, 1 time per a day for 20 days. Derinate is prescribed topically as installation into urethra in the dose 3-5 ml or with tampon into vagina and with simultaneous prescription of microenemas in the dose 10-40 ml for 10 days. Since 10-14 day in exacerbation period in the proliferative stage of an antiherpetic immune response derinate is prescribed by intramuscular injections in the dose 5 ml, 1 time in a day, 10 injections in total number. Then since 6-th day of exacerbation and intake of profluzak psychotherapy seances are carried out. The first seance of rational psychotherapy involves explanation to a patient in available form mechanism of the disease, the necessity of prolonged treatment and motivation for treatment is enhanced by suggestion. The second psychotherapy seance involves neurolinguistic programming wherein a patient colorful and detailed description of desirable function when he imagines achievement of the desire result, and positive emotional and vegetative symptoms are notes and the conditional-reflect association is formed by tactile contact. Under psychotherapist control a patient imagines "part of person" responsible for achievement of the desire result the patient attention is accented for the desire result and arisen physiological responses are fixed by using tactile contact. Also, new behavior methods are proposed to take for a patient that are directed for achievement of the desire result - avoiding sexual contacts during exacerbation of genital herpes in one of partner and during every month hormonal cycles, avoiding stress situations, and in case of each stress situation significant for patient profluzak has to be intake in a single dose 40 mg, using a condom in sexual contact in the exacerbation period. Patient analyzes the proposed new behavior methods that help avoiding relapses, provide good state of health, promotes to recovery process of genitals recovery and selects at least three the most rationally available for him behavior methods. In the case of the positive response that is controlled by physiological symptoms the result is fixed by tactile contact. The third seance involves the suggestive psychotherapy directed for fixing the attained result. The suggestive therapy seance is carried out once per a week for 6 months. Method provides declining the treatment time, to reduce relapse frequency of genital herpes and to recover the emotional state of patient.

EFFECT: improved treatment method.

2 cl, 3 tbl, 1 ex

FIELD: veterinary virology and biotechnology.

SUBSTANCE: invention proposes the strain that possesses high antigenic and immunogenic activity. The strain is deposited in the Collection of microorganism strain FGU VGNKI at the registration name "VNIIZZH-DEP". The coronavirus strain is reproduced in transplanted cell cultures of calf kidney (MDVK, Taurus), calve coronary vessel cells and in heterologous culture of simian cells (Vero). After 3-4 days of incubation at 37°C virus is accumulated in the amount up to 108 particels/cm3 by data of electronic microscopy. The strain shows ability for reproducing in the same accumulation degree in cell culture MDVK at 34°C. The strain possesses high biological, antigenic and immunogenic activity and retains native immunobiological properties after inactivation and can be used in preparing highly sensitive and specific diagnostic, highly immunogenic, harmless and areactogenic vaccine and curative preparations.

EFFECT: valuable properties of strain, improved preparing method.

6 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vestibular and auditory disorders, trigeminal nerve's neuralgia and peripheral paresis of facial nerve of herpetic etiology. The method deals with introduction of an antiherpetic preparation followed by immunomodelling therapy with the use of polyoxidonium. Moreover, after treating with antiherpetic preparation before introducing polyoxidonium it is necessary to conduct additional successive therapy: with preparations of trophic action as milgamma or neuromultivit at simultaneous introduction of antioxidant, then comes intratissue injection of cerebrolysine being behind the top of mastoid process.

EFFECT: the innovation enables to decrease the quantity of relapses due to stopping the development of herpes simplex virus, restore conductivity along nervous fiber and improve endoneural circulation.

3 cl, 3 ex

Up!